Alleging Monopoly, Pension Funds Sue BMS and Generics Firms Over Pay-to-Play Deals

By PacConAdmin | November 23, 2022

Three union pension funds have filed a class action antitrust suit against Bristol Myers Squibb (BMS) and several generic drugmakers claiming the companies conspired to restrict competition on blockbuster blood cancer drug Revlimid (lenalidomide) and share in the profits, thus creating a monopoly.
Source: Drug Industry Daily

Posted in Drug Industry Daily